This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
milla1cf Tue, 04/23/2024 - 15:53 April 23, 2024 — Medtronic plc, a global leader in healthcare technology, today announced the launch of its latest innovation in cardiac surgery, the Avalus Ultra valve. president of the Cardiac Surgery business in the Medtronic Cardiovascular portfolio.
Getty Images milla1cf Thu, 06/13/2024 - 20:38 June 13, 2024 — Medtronic plc, a global leader in healthcare technology, today announced the launch of its latest innovation in cardiac surgery, the Avalus Ultra valve. president of the Cardiac Surgery business in the Medtronic Cardiovascular portfolio.
In his year-long term as President of HVS, Dr. El-Hamamsy will focus on fostering collaboration among cardiologists, surgeons, and researchers, as well as promoting awareness and encouraging innovation to reduce the burden of heart valve disease globally.
A team at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) has developed an innovative gene-therapy strategy that could transform the treatment of arrhythmogenic right ventricular cardiomyopathy type 5 (ARVC5), a rare and highly penetrant inherited cardiac disorder with an elevated risk of suddencardiacdeath.
The co-occurrence of keywords has generated 8 clusters, including DCM, lamin a/c, heart failure, suddencardiacdeath, hypertrophic cardiomyopathy, cardiac hypertrophy, arrhythmogenic cardiomyopathy, and next-generation sequencing.
The EV ICD Pivotal Trial is a prospective, multicenter, single-arm, non-randomized, pre-market clinical study that assessed the safety and effectiveness of the Medtronic EV-ICD system for patients at risk of suddencardiacdeath. Primary results were published in The New England Journal of Medicine.
The work has extended beyond conventional approaches by also utilizing warning symptoms of impending suddencardiacdeath combined with other biological markers. “Dr. Chugh is widely regarded among our electrophysiology community as one of our most innovative, dedicated and talented researchers.
The Smidt Heart Institute recently received CAROL Act funding to study the connection between ventricular arrhythmias—abnormal heartbeats that start in the heart’s two lower chambers—and an elevated risk of suddencardiacdeath in patients with mitral valve disease. Patients come to us from all over the U.S.
The risk of death is extremely low (0.05-0.1%). Technological innovations have made catheter ablation safer and more effective than ever before,” Tzeis, who added, “For example, we now have pulsed field ablation which uses high energy electrical pulses to treat atrial fibrillation without damaging the nerves or oesophagus.
Still, Mirowski”s electrical kid survived the test of time and evolved with great technological innovations from companies like Medtronic, Guidant, Abbot etc. It has, now grown into 45 year old wonder device , that can wake up the heart from death. ICDs faced some foundational questions regarding its utility value vs. risk.
The aim was to determine the role of 4βHC as a prognostic factor in CAD.Methods and ResultsThe ARTEMIS (Innovation to Reduce Cardiovascular Complications of Diabetes at the Intersection) cohort consists of 1946 patients with CAD. Men and women were analyzed separately in quartiles according to plasma 4βHC. P=0.002) and 4.18 (95% CI, 1.5–11.4;P=0.005),
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content